Lisata Therapeutics Statistics

Total Valuation

FRA:8NE has a market cap or net worth of EUR 34.38 million. The enterprise value is 18.17 million.

Market Cap	34.38M
Enterprise Value	18.17M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	8.82M
Shares Outstanding	n/a
Shares Change (YoY)	+3.87%
Shares Change (QoQ)	+1.55%
Owned by Insiders (%)	19.91%
Owned by Institutions (%)	8.40%
Float	7.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	37.69
PB Ratio	2.36
P/TBV Ratio	2.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.17
EV / Sales	20.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.24

Financial Position

The company has a current ratio of 4.72

Current Ratio	4.72
Quick Ratio	4.42
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -72.17% and return on invested capital (ROIC) is -49.47%.

Return on Equity (ROE)	-72.17%
Return on Assets (ROA)	-41.86%
Return on Invested Capital (ROIC)	-49.47%
Return on Capital Employed (ROCE)	-116.80%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	35,075
Profits Per Employee	-597,987
Employee Count	26
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-819,913
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +48.80% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+48.80%
50-Day Moving Average	1.96
200-Day Moving Average	2.04
Relative Strength Index (RSI)	88.79
Average Volume (20 Days)	50

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, FRA:8NE had revenue of EUR 911,961 and -15.55 million in losses. Loss per share was -1.81.

Revenue	911,961
Gross Profit	911,961
Operating Income	-17.11M
Pretax Income	-16.37M
Net Income	-15.55M
EBITDA	-16.97M
EBIT	-17.11M
Loss Per Share	-1.81

Full Income Statement

Balance Sheet

The company has 16.19 million in cash and n/a in debt, with a net cash position of 16.19 million.

Cash & Cash Equivalents	16.19M
Total Debt	n/a
Net Cash	16.19M
Net Cash Per Share	n/a
Equity (Book Value)	14.59M
Book Value Per Share	1.69
Working Capital	14.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.68 million and capital expenditures -23,864, giving a free cash flow of -14.71 million.

Operating Cash Flow	-14.68M
Capital Expenditures	-23,864
Free Cash Flow	-14.71M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,876.54%
Pretax Margin	-1,794.77%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:8NE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.87%
Shareholder Yield	-3.87%
Earnings Yield	-45.23%
FCF Yield	-42.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 15, 2022. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	Sep 15, 2022
Split Type	Reverse
Split Ratio	0.0666666667

Scores

FRA:8NE has an Altman Z-Score of -35.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-35.32
Piotroski F-Score	1